全文获取类型
收费全文 | 28471篇 |
免费 | 1809篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 879篇 |
妇产科学 | 683篇 |
基础医学 | 4309篇 |
口腔科学 | 536篇 |
临床医学 | 4034篇 |
内科学 | 4998篇 |
皮肤病学 | 469篇 |
神经病学 | 2887篇 |
特种医学 | 744篇 |
外科学 | 2376篇 |
综合类 | 222篇 |
一般理论 | 27篇 |
预防医学 | 3388篇 |
眼科学 | 524篇 |
药学 | 2031篇 |
1篇 | |
中国医学 | 57篇 |
肿瘤学 | 2008篇 |
出版年
2023年 | 219篇 |
2022年 | 400篇 |
2021年 | 755篇 |
2020年 | 491篇 |
2019年 | 664篇 |
2018年 | 810篇 |
2017年 | 577篇 |
2016年 | 643篇 |
2015年 | 825篇 |
2014年 | 956篇 |
2013年 | 1533篇 |
2012年 | 2135篇 |
2011年 | 2288篇 |
2010年 | 1194篇 |
2009年 | 1117篇 |
2008年 | 1880篇 |
2007年 | 1948篇 |
2006年 | 1876篇 |
2005年 | 1752篇 |
2004年 | 1657篇 |
2003年 | 1541篇 |
2002年 | 1361篇 |
2001年 | 259篇 |
2000年 | 214篇 |
1999年 | 243篇 |
1998年 | 254篇 |
1997年 | 189篇 |
1996年 | 197篇 |
1995年 | 145篇 |
1994年 | 151篇 |
1993年 | 131篇 |
1992年 | 148篇 |
1991年 | 141篇 |
1990年 | 132篇 |
1989年 | 142篇 |
1988年 | 105篇 |
1987年 | 108篇 |
1986年 | 106篇 |
1985年 | 100篇 |
1984年 | 102篇 |
1983年 | 102篇 |
1982年 | 92篇 |
1981年 | 67篇 |
1980年 | 59篇 |
1979年 | 69篇 |
1978年 | 34篇 |
1977年 | 38篇 |
1976年 | 46篇 |
1975年 | 39篇 |
1974年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
James B. Derr John A. Clark Maryann Morales Eli M. Espinoza Sandra Vadhin Valentine I. Vullev 《RSC advances》2020,10(41):24419
This article reports two discoveries. (1) 2-Methoxyethanol induces unprecedented selectivity for etherification of 5-hydroxy-2-nitrobenzic acids without forming undesired esters. (2) Such compounds are precursors for amides showing unusual robustness against oxidative degradation, essential for molecular electrets that transfer strongly oxidizing holes at about −6.4 eV vs. vacuum.Selective etherification produces precursors for amides resistant to oxidative degradation, i.e., showing reversible oxidation at 1.5 to 1.7 V vs. SCE. 相似文献
992.
993.
994.
Dupuy AJ Clark K Carlson CM Fritz S Davidson AE Markley KM Finley K Fletcher CF Ekker SC Hackett PB Horn S Largaespada DA 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(7):4495-4499
Transposons have been used in invertebrates for transgenesis and insertional mutagens in genetic screens. We tested a functional transposon called Sleeping Beauty in the one-cell mouse embryo. In this report, we describe experiments in which transposon vectors were injected into one-cell mouse embryos with mRNA expressing the SB10 transposase enzyme. Molecular evidence of transposition was obtained by cloning of insertion sites from multiple transgenic mice produced by SB10 mRNA/transposon coinjection. We also demonstrate germ-line transmission and expression from transposed elements. This technique has promise as a germ-line transgenesis method in other vertebrate species and for insertional mutagenesis in the mouse. 相似文献
995.
Pappu AS Bacon SP Illingworth DR 《The Journal of laboratory and clinical medicine》2003,141(4):250-256
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitors are widely used to decrease plasma cholesterol levels in patients with heterozygous familial hypercholesterolemia (FH) who are at increased risk of premature coronary artery disease. Tissue-culture and animal studies have indicated that administration of HMG CoA reductase inhibitors (eg, lovastatin, simvastatin, etc) induces a compensatory increase in the activity of HMG CoA reductase, both by increasing its synthesis and decreasing catabolism. To determine in human subjects whether cessation of therapy with this class of drugs leads to induction of HMG CoA reductase activity and above-normal rates of cholesterol biosynthesis, we measured urinary concentrations of mevalonic acid (an indicator of cholesterol biosynthesis) after the cessation of therapy with lovastatin and simvastatin (80 mg/day) in patients with heterozygous FH. Plasma concentrations of LDL increased promptly on discontinuation of reductase inhibitor therapy but did not increase above pretreatment levels at any point after drug discontinuation. Similarly, the 24-hour urinary excretion of mevalonic acid was reduced during treatment with lovastatin or simvastatin and increased promptly on discontinuation of drug but did not increase to levels exceeding those found at baseline when the patients were receiving dietary therapy only. We conclude that cessation of treatment with HMG CoA reductase inhibitors in patients with FH does not result in a rebound increase in cholesterol biosynthesis and that no rebound overshoot occurs in plasma concentrations of low-density-lipoprotein cholesterol. 相似文献
996.
Angela Bononi Keisuke Goto Guntulu Ak Yoshie Yoshikawa Mitsuru Emi Sandra Pastorino Lorenzo Carparelli Angelica Ferro Masaki Nasu Jin-Hee Kim Joelle S. Suarez Ronghui Xu Mika Tanji Yasutaka Takinishi Michael Minaai Flavia Novelli Ian Pagano Giovanni Gaudino Harvey I. Pass Joanna Groden Joseph J. Grzymski Muzaffer Metintas Muhittin Akarsu Betsy Morrow Raffit Hassan Haining Yang Michele Carbone 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(52):33466
Rare biallelic BLM gene mutations cause Bloom syndrome. Whether BLM heterozygous germline mutations (BLM+/−) cause human cancer remains unclear. We sequenced the germline DNA of 155 mesothelioma patients (33 familial and 122 sporadic). We found 2 deleterious germline BLM+/− mutations within 2 of 33 families with multiple cases of mesothelioma, one from Turkey (c.569_570del; p.R191Kfs*4) and one from the United States (c.968A>G; p.K323R). Some of the relatives who inherited these mutations developed mesothelioma, while none with nonmutated BLM were affected. Furthermore, among 122 patients with sporadic mesothelioma treated at the US National Cancer Institute, 5 carried pathogenic germline BLM+/− mutations. Therefore, 7 of 155 apparently unrelated mesothelioma patients carried BLM+/− mutations, significantly higher (P = 6.7E-10) than the expected frequency in a general, unrelated population from the gnomAD database, and 2 of 7 carried the same missense pathogenic mutation c.968A>G (P = 0.0017 given a 0.00039 allele frequency). Experiments in primary mesothelial cells from Blm+/− mice and in primary human mesothelial cells in which we silenced BLM revealed that reduced BLM levels promote genomic instability while protecting from cell death and promoted TNF-α release. Blm+/− mice injected intraperitoneally with asbestos had higher levels of proinflammatory M1 macrophages and of TNF-α, IL-1β, IL-3, IL-10, and IL-12 in the peritoneal lavage, findings linked to asbestos carcinogenesis. Blm+/− mice exposed to asbestos had a significantly shorter survival and higher incidence of mesothelioma compared to controls. We propose that germline BLM+/− mutations increase the susceptibility to asbestos carcinogenesis, enhancing the risk of developing mesothelioma.In the United States, the incidence rate of mesothelioma varies between fewer than one case per 100,000 persons in states with no asbestos industry to two to three cases per 100,000 persons in states with an asbestos industry (1, 2). Asbestos causes DNA damage and apoptosis (3) and promotes a chronic inflammatory reaction that supports the emergence of malignant cells (4). Fortunately, only a small fraction of exposed individuals develop mesothelioma; for example, 4.6% of deaths in miners who worked in asbestos mines for over 10 y were caused by mesothelioma (1). Therefore, multiple cases of mesothelioma in the same family are rare and suggest genetic predisposition (5). In 2001, we discovered that susceptibility to mesothelioma was transmitted in a Mendelian fashion across multiple generations in some Turkish families exposed to the carcinogenic fiber erionite, pointing to gene × environment interaction (G×E) as the cause (6). In 2011, we discovered that carriers of heterozygous germline BRCA1-associated protein–1 (BAP1) mutations (BAP1+/−) developed mesothelioma and uveal melanoma (5), findings expanded and confirmed by us and by multiple research teams (reviewed in refs. 1, 7, 8). Moreover, heterozygous germline Bap1 mutations (Bap1+/−) significantly increased susceptibility to asbestos-induced mesothelioma in mice (9, 10), evidence of G×E. Reduced BAP1 levels impair DNA repair (11) as well as different forms of cell death (3, 12) and induce metabolic alterations (13–15) that together favor cancer development and growth.Recent studies revealed that mesothelioma may also develop among carriers of germline mutations of additional tumor-suppressor genes that cause well-defined cancer syndromes, including MLH1 and MLH3 (Lynch syndrome), TP53 (Li–Fraumeni syndrome), and BRCA1-2 (Breast and Ovarian Cancer syndrome) (16, 17). When all germline mutations are combined, it has been estimated that about 12% of mesotheliomas occur in carriers of heterozygous germline mutations of BAP1, the most frequent mutation among patients with mesothelioma, or of other tumor suppressors. Some of these mutations may sensitize the host to asbestos carcinogenesis, according to a G×E scenario (17). Thus, presently, mesothelioma is considered an ideal model to study G×E in cancer (17). As part of the Healthy Nevada Project (HNP), we are studying G×E in northern Nevada, a region with an unusually high risk of exposure to carcinogenic minerals and arsenic, which may be related to the high cancer rates in this region (18). We are investigating genetic variants that may increase cancer risk upon exposure to carcinogens to implement preventive strategies.Biallelic mutations of the Bloom syndrome gene (BLM) cause Bloom syndrome, an autosomal-recessive tumor predisposition syndrome characterized by pre- and postnatal growth deficiency, photosensitivity, type 2 diabetes, and greatly increased risk of developing various types of cancers. BLM is a RecQ helicase enzyme that modulates DNA replication and repair of DNA damage by homologous recombination (19). In patients affected by Bloom syndrome, the absence of the BLM protein causes chromosomal instability, increased number of sister chromatid exchanges, and increased numbers of micronuclei (20–22). In addition, BLM is required for p53-mediated apoptosis (23), a process critical to eliminate cells that have accumulated DNA damage. Impaired DNA repair together with altered apoptosis resulted in increased cancer incidence (17, 24). Of course, inactivating germline BLM heterozygous (BLM+/−) mutations are much more common than biallelic BLM (BLM−/−) mutations, with an estimated frequency in the general population of 1 in 900 based on data from the Exome Aggregation Consortium (25). BLM+/− mutation carriers do not show an obvious phenotype; however, some studies have suggested that carriers of these mutations may have an increased cancer risk (17, 24). Mice carrying Blm+/− mutations are prone to develop a higher rate of malignancies in the presence of contributing factors, such as concurrent heterozygous mutations of the adenomatous polyposis coli (Apc) gene, or upon infection with murine leukemia virus (26). However, in studies in which Blm+/− mice were crossed with tuberous sclerosis 1-deficient (Tsc1+/−) mice that are predisposed to renal cystadenomas and carcinomas, Wilson et al. found that Tsc1+/− Blm+/− mice did not show significantly more renal cell carcinomas compared with Tsc1+/− BlmWT mice (27). In humans, a large study involving 1,244 patients with colon cancer and 1,839 controls of Ashkenazi Jewish ancestry, in which BLM+/− frequency is as high as 1 in 100 individuals (28), suggested that carriers of germline BLM+/− mutations might have a twofold increase in colorectal cancer (CRC) (29). A smaller study did not confirm these results, but reported a trend of increasing incidence of adenomas—premalignant lesions—among BLM+/− mutation carriers (30). In addition, BLM+/− mutations were found overrepresented among early-onset (<45 y old) CRC patients (25). Other studies associated BLM+/− mutations to an increased risk of breast (31, 32) and prostate cancer (33), but the low power of these studies hampered definite conclusions. In summary, it appears possible that BLM+/− mutations may increase cancer risk in the presence of contributing factors. 相似文献
997.
998.
The aim of this study was to correlate the activity of superoxide dismutase, catalase and glutathion peroxidase in liver and brain of 1, 4 and 18 months old CBA mice of both sexes. In liver, decreased superoxide dismutase and increased glutathione peroxidase activities were observed during aging in male mice. In brain, the increase of catalase and glutathion peroxidase activity during aging was observed only in female mice. Regardless of tissue examined, different sex-related correlation pattern of antioxidant enzyme activity was demonstrated in young and old mice. The cooperation between antioxidant enzymes becomes more coherent with increased lipid peroxidation concentration in liver and brain of older female mice. On the contrary, in older male mice the link among three antioxidant enzymes becomes weaker, regardless of lipid peroxidation concentration which increased in liver and decreased in brain during aging. In older mice lower partial coefficient of correlation than pair correlation demonstrates the influence of the third party in the cooperation of two antioxidant enzymes. The results imply stronger correlative links in old female than male mice, which might explain why old females are better protected from oxidative stress than males. 相似文献
999.
1000.
BackgroundPeripheral artery disease (PAD) screening may be performed to prevent progression of PAD or future cardiovascular disease in general. Recommendations for PAD screening have to be derived indirectly because no randomized trials comparing screening versus no screening have been performed. We performed a systematic review of guidelines to evaluate the value of PAD screening in asymptomatic adults.MethodsGuidelines in English published between January 1, 2003 and January 20, 2011 were retrieved using MEDLINE, CINAHL, the National Guideline Clearinghouse, the National Library for Health, the Canadian Medication Association Infobase, and the G-I-N International Guideline Library. Guidelines developed by national and international medical societies from Western countries, containing recommendations on PAD screening, were included. Two reviewers independently assessed rigor of guideline development using the Appraisal of Guidelines Research and Evaluation (AGREE) instrument. One reviewer performed full extraction of recommendations, which was validated by a second reviewer.ResultsOf 2779 titles identified, 8 guidelines were included. AGREE scores varied from 33% to 81%. Five guidelines advocated PAD screening, others found insufficient evidence for PAD screening or were against it. Measurement of the ankle-brachial index (ABI) was generally recommended for middle-aged populations with elevated cardiovascular risk levels. Those identified as having PAD are reclassified as high risk, warranting intensive preventive interventions to reduce their risk of a cardiovascular event. The underlying evidence mainly consisted of studies performed in patients with established PAD. A meta-analysis that evaluated ABI testing in the context of traditional cardiovascular risk assessment was interpreted differently.ConclusionsRecommendations on PAD screening vary across current guidelines, making the value of PAD screening uncertain. The variation seems to reflect lack of studies that show added value of detection of early PAD beyond expectant management and traditional risk assessment. 相似文献